Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
10 hedge funds and large institutions have $7.33M invested in Iterum Therapeutics in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.85% less ownership
Funds ownership: 3.15% → 2.3% (-0.85%)
29% less funds holding
Funds holding: 14 → 10 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
62% less capital invested
Capital invested by funds: $19.1M → $7.33M (-$11.7M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.34M |
| 2 |
Two Sigma Investments
New York
|
+$167K |
| 3 |
ML
McAdam LLC
Philadelphia,
Pennsylvania
|
+$31.7K |
| 4 |
BG
Bollard Group
Boston,
Massachusetts
|
+$7.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.68M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$653K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$515K |
| 4 |
Goldman Sachs
New York
|
-$51K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$49K |
ITRM Hedge Fund Activity: Q2 2020 in Review
10 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q2 2020, worth a combined $7.33M — down 62% from $19.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ITRM and 4 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.34M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $4.68M sold.
- 10 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2020, down from 14 in Q1 2020.
- Funds reported $7.33M of Iterum Therapeutics stock for Q2 2020, down 62% quarter-over-quarter.
- 4 funds opened new Iterum Therapeutics positions in Q2 2020 and 8 closed out, a net change of -4 holders.
- The largest Iterum Therapeutics buyer in Q2 2020 was Armistice Capital, an estimated $3.34M added.
- The largest Iterum Therapeutics seller in Q2 2020 was Sofinnova Investments, an estimated $4.68M sold.
Based on aggregated 13F filings for Q2 2020.